The randomized, single-blind Phase I trial is designed to evaluate potential control formulations for future NGX-1998 clinical trials. NeurogesX expects to complete the trial by the end of 2008.
The objective of the NGX-1998 development program is to determine the ability of NGX-1998 to provide protracted pain relief from a single treatment.
Anthony DiTonno, president and CEO of NeurogesX, said: “The initiation of this Phase I trial of NGX-1998 marks a significant step in our program to develop a second-generation liquid formulation of capsaicin to manage pain. We believe that our Phase I trial will provide us with important information that will help shape the design of further studies with the product candidate.”